Nimodipine-refractory reversible cerebral vasoconstriction syndrome treated effectively with verapamil

So Young Park¹, Joon Ho Lee¹, In Ja Shin¹, Raul G. Nogueira²,³, Jin Soo Lee¹,²,³

¹Department of Neurology, Ajou University Hospital, Ajou University School of Medicine, Suwon, Korea
²Department of Neurology and Radiology, Emory University, Atlanta, GA, USA
³Neuroendovascular Service, Grady Memorial Hospital, Atlanta, GA, USA

ABSTRACT

Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by recurrent thunderclap headache and reversible multifocal vasoconstrictions of the cerebral arteries with or without focal neurologic deficits [1]. When diagnosing RCVS, other intracranial angiopathies that manifest with a similar angiographic findings should be excluded; examples of such pathologies include primary angiitis of the central nervous system, aneurysmal subarachnoid hemorrhage (SAH), moyamoya disease, and intracranial arterial dissection [1]. While there are no guidelines for the management of RCVS, nimodipine, which is used to treat vasospasm in SAH, is widely used for RCVS.

We report a case of RCVS that did not respond to per os (PO) nimodipine or steroid administration. Temporary recovery was observed after administration of intra-arterial (IA) verapamil, but improvement was only achieved after replacing PO nimodipine with PO verapamil.

Keywords: Nimodipine; Reversible cerebral vasoconstriction syndrome; Verapamil

INTRODUCTION

Reversible cerebral vasoconstriction syndrome (RCVS) is defined as a sudden onset of severe headache and multiple reversible segmental vasoconstrictions of the cerebral arteries with or without focal neurologic deficits [1]. When diagnosing RCVS, other intracranial angiopathies that manifest with a similar angiographic findings should be excluded; examples of such pathologies include primary angiitis of the central nervous system, aneurysmal subarachnoid hemorrhage (SAH), moyamoya disease, and intracranial arterial dissection [1]. While there are no guidelines for the management of RCVS, nimodipine, which is used to treat vasospasm in SAH, is widely used for RCVS.

We report a case of RCVS that did not respond to per os (PO) nimodipine or steroid administration. Temporary recovery was observed after administration of intra-arterial (IA) verapamil, but improvement was only achieved after replacing PO nimodipine with PO verapamil.
CASE REPORT

This is a retrospective case study. Written informed consent by the following patient was waived due to a retrospective nature of our study.

A 52-year-old woman was referred to our hospital by a local clinic. She presented with recurrent episodes of severe thunderclap headache with 10 of a numeric rating scale score (maximum, 10) for the past 7 days accompanied by nausea and vomiting. Her headache lasted for about 2 hours after taking the pain reliever, then slightly improved, worsened again in 5 hours, and there was no significant exacerbation factor. Apart from dyslipidemia that was being treated with rosuvastatin, she had no other pertinent findings in her past medical history. The patient did not show any neurologic deficits on neurological examination, and there was no evidence of inflammation in cerebrospinal fluid (CSF) and serological testing. A brain magnetic resonance imaging with angiography was taken at the local clinic which documented multifocal stenoses on bilateral anterior cerebral arteries (ACAs) and M2 segments middle cerebral arteries (MCAs) without ischemic or hemorrhagic complications. Upon admission in our hospital, digital subtraction angiography (DSA) showed the same findings (Fig. 1). Treatment was started with PO nimodipine 60 mg three times a day.

Computed tomography angiography (CTA) was performed on hospital day 9 and showed worsening of vasoconstriction in multiple areas despite the mild improvement of the patient's headache without focal neurologic symptom from hospital day 4. Repeat DSA revealed severe vasoconstriction in the bilateral ACAs and MCAs (Fig. 1). A total of 4 mg of IA verapamil was slowly infused in both internal carotid arteries, after which the vessels normalized angiographically (Fig. 1). After the procedure, the PO nimodipine was still administered, and pain relievers that were helpful intermittently were stopped entirely. Favorably, her headache did not worsen until discharge. However, on day 11, CTA revealed recurrent multifocal vasoconstrictions (Fig. 1). Although vasculitis serology tests were negative, PO glucocorticoids were empirically added for presumed inflammation. However, these treatments failed to resolve the vasoconstrictions (Fig. 1).

Based on the patient's responsiveness to IA verapamil, PO verapamil was administered and titrated to 240 mg slow release form (SR) twice a day. While increasing verapamil gradually, the blood pressure decreased, but no significant hypotension was observed, and there were no other side effects.

Fig. 1. Timeline of the order of drugs administered to the patient and changes in blood vessel conditions. On hospital day (HD) 1, initial digital subtraction angiography (DSA) showed multifocal stenoses on the M2 division of the right middle cerebral artery and the ipsilateral anterior cerebral artery. On HD 9, upon treatment with per os (PO) nimodipine, repeat DSA showed aggravated diffuse vasoconstrictions with “string of beads” appearance in middle cerebral artery branches which resolved following intra-arterial (IA) verapamil infusion. On HD 11, vasoconstriction recurred 2 days after treatment with PO nimodipine. On HD 15, no definite interval changes in vascular status were noted. On HD 18, recovery of the diffuse vasoconstrictions was observed after PO verapamil was administered. On HD 90, the appearance of the cerebral arteries had returned to normal and verapamil was tapered and then discontinued.
Nimodipine was discontinued and the PO glucocorticoid was tapered off for 4 days. Follow-up CTA showed a substantial improvement with only mild residual narrowing of several vessels (Fig. 1) and the patient was discharged. After 3 months, CTA showed complete normalization of the previous areas of stenosis, and PO verapamil was tapered and then discontinued. Repeat CTA 7 months after discharge showed normal findings.

**DISCUSSION**

RCVS is characterized by reversible segmental vasoconstriction of the cerebral arteries and subsequent dilation; this condition usually manifests as a thunderclap headache with or without neurologic symptoms [2]. The criteria required to diagnose RCVS are as follows: (1) normal or near-normal CSF analysis results, (2) documentation of multifocal segmental cerebral artery narrowing on DSA or CTA, (3) absence of evidence of aneurysmal SAH, and (4) reversibility of angiographic abnormalities within 12 weeks after onset [3]. Angiographic findings consistent with RCVS include several smooth or tapered stenosis of the medium and large arteries with normal or dilated arterial segments resulting in a “bead and string” or “sausage and string” appearance [4]. Most patients with RCVS have a benign clinical course. Approximately 80% of the patients have excellent clinical outcomes at short-term follow-up after 2 to 4 months [1]. However, some RCVS patients experience progressive vasoconstriction and disabling

**Table 1. Comparison of nimodipine and verapamil [14,17]**

<table>
<thead>
<tr>
<th>Drug class</th>
<th>Nimodipine</th>
<th>Verapamil</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generation of CCBs</td>
<td>2nd generation</td>
<td>1st generation</td>
</tr>
<tr>
<td>Half-life</td>
<td>8–9 hr</td>
<td>3–7 hr</td>
</tr>
<tr>
<td>Distribution of receptors</td>
<td>Vascular smooth muscle cells (cerebral &gt; peripheral)</td>
<td>Vascular smooth muscle cells (coronary, cerebral)</td>
</tr>
<tr>
<td>Vasodilatory mechanism</td>
<td>Block L-type voltage-gated calcium channels</td>
<td>Block L- and T-type voltage gated calcium channels</td>
</tr>
<tr>
<td>Approved indications</td>
<td>Vasospasm following subarachnoid hemorrhage, Migraine</td>
<td>Cluster headache, Hypertension, Tachyarrhythmia (atrial fibrillation, atrial flutter, supraventricular tachycardia)</td>
</tr>
<tr>
<td>Contraindications</td>
<td>Severe hypotension</td>
<td>Severe hypotension, Severe congestive heart failure, Sick sinus syndrome, Second- or third-degree atrioventricular block, Atrial fibrillation with Wolff-Parkinson-White syndrome</td>
</tr>
<tr>
<td>Side effects</td>
<td>Pruritus, Gastrointestinal hemorrhage, Thrombocytopenia, Vomiting, Diaphoresis, Congestive heart failure</td>
<td>Constipation, Dizziness, Nausea, Low blood pressure, headache</td>
</tr>
<tr>
<td>Extended-release formulation</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Drug interaction</td>
<td>Decreased by macrolides and antifungal agents</td>
<td>Decreased by rifampin, erythromycin, Increased by colchicine, midazolam</td>
</tr>
</tbody>
</table>

CCB, calcium-channel blocker.
stroke despite receiving calcium channel blockers (CCBs) or glucocorticoids [1,5].

No randomized control trials for the management of RCVS have been conducted. However, it has been reported that the use of CCBs is associated with good outcomes; therefore, these drugs have been widely used as the first-line therapy in patients with RCVS [1]. Nimodipine is a dihydropyridine CCB that acts mainly on vascular smooth muscle. Nimodipine is lipophilic, crosses the blood-brain barrier and longer-acting compared to other CCBs [6,7]. Randomized controlled trials have shown that PO nimodipine can improve clinical outcomes in patients with cerebral vasospasm after SAH [8,9]. Furthermore, because of its selective affinity for cerebral arteries beyond the blood-brain barrier [10], nimodipine has been reported to shorten the clinical course of RCVS when administered early [11]; however, it has not been shown to confer any benefit regarding resolving vasoconstriction and preventing complications [11]. Even despite early nimodipine treatment, vasoconstriction can be worsened and later improved, apart from improving clinical symptoms [12]. In our case, nimodipine could only provide symptomatic relief by reducing the severity and frequency of headaches; it did not help resolve the patient’s multifocal stenosis and even aggravated the vessel status. There have been previous literature that cerebral vascular focal stenosis in RCVS patients is associated with the occurrence of complications such as ischemic stroke [12]. Therefore, we have considered other therapeutic options that can be expected to improve vasoconstriction.

Verapamil is widely used to treat variant angina secondary to coronary vasospasm and has been reported to improve vasospasm without hypertensive intracranial complications [13]. The pathophysiology of variant angina is similar to that of RCVS in that both exhibit reversible arterial vasoconstric-

---

**Fig. 2.** Proposal of a novel strategy for reversible cerebral vasoconstriction syndrome (RCVS) diagnosis and treatment. CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; IA, intra-arterial; PO, per os; DSA, digital subtraction angiography.
Verapamil is a phenylalkylamine (non-dihydropyridine) CCB with a half-life shorter than nimodipine (Table 1) that acts on the smooth muscles of the cerebral arteries, which are structurally similar to the coronary arteries [14]. Although experiments have demonstrated a short duration of effect, it has been suggested that verapamil is amphiphilic and has a wide distribution in the brain, thereby allowing it to persist in the patient’s body [15]. While nimodipine has a relatively longer duration of effect compared to verapamil, the effects of both drugs disappear within 2 hours [14]. Therefore, it is important to ensure that a drug’s duration of effect will persist after the intervention is given. As for PO administration, a study reported that administration of slow-releasing verapamil was more effective than nimodipine in patients with RCVS [16]. Characteristics between nimodipine and verapamil are compared in Table 1 [14,17].

IA administration of verapamil in patients with refractory and progressive RCVS was suggested as another effective therapeutic option [18,19]. In contrast to PO or intravenous administration, this targeted approach reduces the possibility of persistent systemic hypotension, thus avoiding concerns about the occurrence of infarction in vascular border zones [19]. IA administration of verapamil is suggested to be both, a diagnostic tool and therapeutic option for patients with severe refractory RCVS. Recent studies have reported that vascular changes after administration of IA verapamil or other vasodilators such as nicardipine or milrinone can aid in diagnosing RCVS [20,21].

In summary, we report the case of a patient diagnosed with RCVS who experienced worsening vasoconstriction despite treatment with PO nimodipine and glucocorticoids. While vascular recovery was observed after IA administration of verapamil, multifocal stenoses reformed during the PO nimodipine treatment. The patient’s vessel status normalized after replacing PO nimodipine with PO verapamil. Based on this case, we propose a bridging treatment for RCVS composed of emergent DSA and IA verapamil challenges and PO verapamil titration as an alternative of nimodipine (Fig. 2). Larger prospective studies are warranted to verify the appropriate dose for treatment and the efficacy and safety of these methods.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES


ORCID

So Young Park https://orcid.org/0000-0002-8625-6968
Joon Ho Lee https://orcid.org/0000-0002-6637-1352
In Ja Shin https://orcid.org/0000-0002-7260-1409
Raul G. Nogueira https://orcid.org/0000-0003-4532-153X
Jin Soo Lee https://orcid.org/0000-0002-7225-6166

AUTHOR CONTRIBUTIONS

Conception or design: SYP, JSL.
Acquisition, analysis, or interpretation of data: SYP, RGN, JSL.
Drafting the work or revising: SYP, RGN, JSL.
Final approval of the manuscript: SYP, JHL, IJS, RGN, JSL.

https://doi.org/10.23838/pfm.2020.00198


